S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:KERN

Akerna (KERN) Stock Forecast, Price & News

$0.17
-0.01 (-5.44%)
(As of 09/27/2023 ET)
Compare
Today's Range
$0.17
$0.20
50-Day Range
$0.18
$0.61
52-Week Range
$0.17
$2.80
Volume
438,944 shs
Average Volume
334,937 shs
Market Capitalization
$1.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Akerna MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
475.4% Upside
$1.00 Price Target
Short Interest
Healthy
1.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Akerna in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars


KERN stock logo

About Akerna (NASDAQ:KERN) Stock

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

KERN Price History

KERN Stock News Headlines

Akerna (NASDAQ:KERN) vs. SBI (OTCMKTS:SBHGF) Financial Survey
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Akerna (NASDAQ:KERN) Stock Price Up 7.1%
Why Akerna Stock Is Exploding Higher Today
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Akerna (NASDAQ: KERN)
Akerna to Sell its Cannabis Software Business
Akerna Provides Update on Recently Announced Transactions
See More Headlines
Receive KERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akerna and its competitors with MarketBeat's FREE daily newsletter.

KERN Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Nondepository credit institutions
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KERN
Fax
N/A
Employees
112
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+428.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-79,060,000.00
Net Margins
-251.68%
Pretax Margin
-175.32%

Debt

Sales & Book Value

Annual Sales
$13.65 million
Book Value
($1.52) per share

Miscellaneous

Free Float
7,556,000
Market Cap
$1.48 million
Optionable
Not Optionable
Beta
2.67
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Jessica Billingsley (Age 45)
    Founder, CEO & Chairman
    Comp: $304.5k
  • Mr. Larry Dean Ditto Jr. (Age 56)
    Chief Financial Officer
    Comp: $159.47k
  • Mr. David R. McCullough (Age 46)
    Chief Technology Officer
    Comp: $240.43k
  • Georgia Jablon
    Communications Mang.













KERN Stock - Frequently Asked Questions

Should I buy or sell Akerna stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akerna in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KERN, but not buy additional shares or sell existing shares.
View KERN analyst ratings
or view top-rated stocks.

What is Akerna's stock price forecast for 2023?

1 analysts have issued 12 month target prices for Akerna's stock. Their KERN share price forecasts range from $1.00 to $1.00. On average, they expect the company's share price to reach $1.00 in the next year. This suggests a possible upside of 428.5% from the stock's current price.
View analysts price targets for KERN
or view top-rated stocks among Wall Street analysts.

How have KERN shares performed in 2023?

Akerna's stock was trading at $0.6902 at the start of the year. Since then, KERN shares have decreased by 72.6% and is now trading at $0.1892.
View the best growth stocks for 2023 here
.

Are investors shorting Akerna?

Akerna saw a increase in short interest in September. As of September 15th, there was short interest totaling 123,400 shares, an increase of 1,032.1% from the August 31st total of 10,900 shares. Based on an average trading volume of 315,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.9% of the company's stock are sold short.
View Akerna's Short Interest
.

When is Akerna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our KERN earnings forecast
.

How were Akerna's earnings last quarter?

Akerna Corp. (NASDAQ:KERN) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.20. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.66 million. Akerna had a negative trailing twelve-month return on equity of 475.50% and a negative net margin of 251.68%.

What ETF holds Akerna's stock ?

Amplify Seymour Cannabis ETF holds 13,319 shares of KERN stock, representing 0.03% of its portfolio.

What other stocks do shareholders of Akerna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akerna investors own include KushCo (KSHB), Organigram (OGI), Supreme Cannabis (SPRWF), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Medical Marijuana (MJNA), MariMed (MRMD), Matinas BioPharma (MTNB), CNBX Pharmaceuticals (CNBX) and DHT (DHT).

What is Akerna's stock symbol?

Akerna trades on the NASDAQ under the ticker symbol "KERN."

How do I buy shares of Akerna?

Shares of KERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akerna's stock price today?

One share of KERN stock can currently be purchased for approximately $0.19.

How much money does Akerna make?

Akerna (NASDAQ:KERN) has a market capitalization of $1.48 million and generates $13.65 million in revenue each year. The company earns $-79,060,000.00 in net income (profit) each year or ($7.37) on an earnings per share basis.

How many employees does Akerna have?

The company employs 112 workers across the globe.

How can I contact Akerna?

Akerna's mailing address is 1601 ARAPAHOE STREET, DENVER CO, 80202. The official website for the company is www.akerna.com. The company can be reached via phone at 888-932-6537 or via email at ir@akerna.com.

This page (NASDAQ:KERN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -